Do these 3 things before closing this tab:
1Fix the driver behind crashes, sound loss and screen glitches2Repair Windows errors before they cause bigger problems3Scan for outdated or missing drivers - takes under a minuteResearchers report that colorectal cancer cells can activate a YAP1-linked tissue-repair program associated with metastasis. In mouse models, ceramide production connected a high-fat diet to YAP1 activation, and genetically targeting YAP1 or ceramide-production genes reduced liver metastasis. Human gene-expression analyses found associations involving YAP1 activity, BMI and survival—but they do not show that a particular diet causes metastasis in people. The findings are not dietary advice or an available treatment.
What pathway did the researchers identify?
The study, “Ceramide synthesis mediates colorectal cancer metastasis through a YAP-driven regenerative program,” describes a YAP1-linked program that metastatic colorectal cancer cells appear to use. YAP1 is a gene-regulating protein; in this proposed pathway, its activation switches on genes associated with development, stem-cell maintenance and tissue regeneration.
Regeneration is a normal part of gut repair: after severe injury or infection, cells help rebuild the intestinal lining. The researchers propose that some tumor cells hijack this repair state, using it to support proliferation and migration as cancer progresses. Lead author Swagata Goswami described the tumor cells as co-opting a program normally seen when the gut needs to regenerate.
How do ceramides and YAP1 fit together?
In the mouse studies summarized by MIT, a high-fat diet activated enzymes involved in producing ceramides. The researchers propose that ceramides release a molecular brake that normally keeps YAP1 inactive. YAP1 can then enter the nucleus and switch on target genes in the regenerative program.
The proposed chain is therefore: diet-related changes in mice, increased ceramide production, YAP1 activation, and a gene program that may help tumor cells grow and move. This is a proposed mechanism supported by the reported mouse findings, not proof that the same dietary sequence causes metastasis in people.
What evidence comes from mice, and what comes from people?
| Evidence | What was reported | What it establishes |
|---|---|---|
| Mouse models | Genetically targeting YAP1 or genes involved in ceramide production markedly reduced liver metastasis. The high-fat-diet link to ceramide production and YAP1 activation was also reported in mouse studies. | Intervening in these targets affected metastasis in the studied models. It does not establish a human treatment or prove that a high-fat diet causes human metastasis. |
| Human RNA-sequencing analyses | Researchers reported greater YAP1 activity in metastatic cancer cells, higher expression of YAP1-activated genes among patients with higher BMI, and lower survival among patients with higher levels of those genes. | These are reported associations. They do not show that BMI or diet caused pathway activation, metastasis or lower survival. |
MIT’s summary does not provide sample counts, effect sizes or confidence intervals, so those figures cannot be assessed from the available account. The published paper is linked above; its methods and detailed results are needed to evaluate the findings at that level.
Does this mean a high-fat diet causes colorectal cancer to spread?
No such conclusion is established by the reported evidence. The high-fat-diet result is from mouse studies. In people, the reported BMI and survival patterns come from analyses of gene-expression data and show association, not cause and effect. The findings also do not establish that obesity is required for the YAP1 program: MIT quotes senior author Omer Yilmaz saying the program is not specific to obesity, although it may become more pronounced in obesity.
Could this lead to a treatment?
The researchers plan to explore drugs that inhibit DEGS1 and DEGS2, enzymes involved in ceramide production. This is a future drug-development direction, not a treatment patients can use now. The study summary does not establish the safety or effectiveness of inhibiting these enzymes in people with cancer.
Quick wins for a faster PC:
Scan for outdated or missing drivers - takes under a minuteDriver Scan →Repair Windows errors before they cause bigger problemsFix Now →Ceramides are also essential in healthy tissues. Any medicine that changes their production would need to act selectively enough to avoid disrupting normal tissue functions. MIT says the findings do not yet translate into dietary advice for people already diagnosed with cancer.
What the report does—and does not—support
- Supported by the report: metastatic colorectal cancer cells were associated with a YAP1-driven regenerative program, and genetic targeting of YAP1 or ceramide-production genes reduced liver metastasis in mouse models.
- Not established: that a high-fat diet causes metastasis in people, that changing diet will prevent spread, or that a ceramide-targeting treatment is available.
- Practical implication: patients should not use this report as a reason to change diet, take ceramide-related supplements or seek an unapproved pathway-targeting drug. Discuss treatment and dietary questions with a qualified clinician.
Study and authors
MIT reported the study on September 24, 2026, and says it appears in Science. The senior authors are Omer Yilmaz, Nilay Sethi and Alpaslan Tasdogan; the lead authors are Swagata Goswami, Qiming Zhang and Abdullah Burak Yildiz. MIT’s account says the work used tumor organoids from mouse models and patients with colorectal cancer. See the MIT News summary and the Science paper for the study report and publication details.
Quick Recap
Best Value
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
